ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
PTC Announces Regulatory Update on Risdiplam for Spinal Muscular Atrophy
April 13, 2020PTC Therapeutics announced the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for its review of the New Drug Application (NDA) of risdiplam to August 24, 2020. -
US regulator postpones decision on Roche’s SMA drug risdiplam
April 09, 2020The US Food and Drug Administration (FDA) has postponed the decision on Roche’s new drug application (NDA) of risdiplam to treat spinal muscular atrophy (SMA).
Pharma Sources Insight January 2025
